Glycoproteomics-based Liquid-biopsy LDT Development Service for Pancreas Carcinoma

Glycoprotein Biomarkers for the Diagnosis of Pancreas Carcinoma

Pancreas carcinoma is characterized by a poor prognosis, often diagnosed at an incurable stage due to the lack of early symptoms. One commonly used serum glycoprotein biomarker is the carbohydrate antigen (CA19-9), which is structurally a sialylated Lewis A antigen present on various proteins. However, CA19-9 has limitations, including its reliance on the Lewis-negative genotype. Consequently, there is an urgent need for a more reliable and universally applicable biomarker or panel for diagnosing pancreatic cancer. Glycan structures of glycoproteins undergo alternations in pancreas carcinoma, detectable in biological fluids of cancer patients. Recent advancements in glycoproteomic technology, particularly mass spectrometry, have enabled researchers to explore alternative serum glycoprotein biomarker candidates that can overcome the limitations of CA19-9. This innovative approach offers the potential to discover new markers that could enhance the accuracy and reliability of early pancreatic cancer diagnosis.

Glycoproteomics-based Liquid-biopsy LDT Development for Pancreas Carcinoma at Creative Biolabs

Creative Biolabs is proud to launch Glycoproteomics-based Liquid-biopsy LDT Development for pancreas carcinoma. Our LDT development facilitates the discovery of serum glycoprotein biomarkers from large-scale detection of liquid biopsy samples and we provide a comprehensive analysis of glycoproteomic data. Through our glycoproteomics-based liquid-biopsy LDT services, the identification of a promising serum glycoprotein biomarker or biomarker panel for pancreatic carcinoma becomes attainable.

Fig.1 LDT development for serum biomarker discovery.

Advantages of Our LDT Services

• High-throughput analysis: dealing with a large number of samples
• High-precision detection: utilizing effective fragmentation methods
• Comprehensive services: combining with performance analysis of candidate biomarkers
• Professional team of experts with extensive experience

Published Data

Technology: Glycoproteomic analysis

Journal: Journal of Proteome Research

Published: 2014

Results: A panel of markers, including AACT, THBS1, HPT, and CA 19−9, exhibits significant diagnostic potential for distinguishing pancreatic cancer from other conditions.

Fig.2 Performance of biomarker panels.¹

At Creative Biolabs, our LDT services in tandem with advanced analytical techniques hold great promise for identifying a more effective biomarker to address the challenges associated with pancreatic carcinoma diagnosis. Please don't hesitate to contact us for more information.

Reference

1. Nie, Song, et al. "Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis." Journal of proteome research 13.4 (2014): 1873-1884.

Related Services:

1. NASH
2. NSCLC
3. Renal Cell Carcinoma
4. Nasopharyngeal Carcinoma
5. HCC
6. Advanced Adenoma
7. Colorectal Cancer
8. Prostate Cancer